Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly

This drugmaker should have a basketful of growth drivers over the next decade.Eli Lilly (LLY -1.10%) stands atop the biopharmaceutical world. It's the biggest drugmaker by far based on market cap. Lilly's share price has skyrocketed nearly 700% over the last five years and is up close to 55% in 2024.Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and Zepbound aren' ...